Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SPR | P35270 | 1/20 | 0.54 |
| ▸ | P2RX7 | Q99572 | 6/20 | 0.51 |
| ▸ | EPHX2 | P34913 | 8/20 | 0.50 |
| ▸ | FAAH | O00519 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.45 |
| ▸ | CYP2J2 | P51589 | 2/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | VNN1 | O95497 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13873871 | 0.94 | EPHX2 (0.56) | SPRP2RX7EPHX2FAAHCYP2C9 | |
| SCHEMBL13873783 | 0.91 | EPHX2 (0.61) | SPRP2RX7EPHX2CYP2C9CYP2J2 | |
| SCHEMBL13873868 | 0.85 | EPHX2 (0.68) | SPRP2RX7EPHX2FAAHCYP2C9 | |
| SCHEMBL13873822 | 0.83 | P2RX7 (0.52) | SPRP2RX7EPHX2SMN1; SMN2L3MBTL1 | |
| SCHEMBL13874097 | 0.81 | EPHX2 (0.55) | P2RX7EPHX2SMN1; SMN2L3MBTL1CYP2C19 | |
| SCHEMBL13873597 | 0.79 | EPHX2 (0.65) | SPREPHX2FAAHCYP2C9CYP2J2 | |
| SCHEMBL13873782 | 0.79 | MEN1 (0.51) | SPREPHX2CYP2C9VNN1 | |
| SCHEMBL13873840 | 0.78 | EPHX2 (0.62) | P2RX7EPHX2SMN1; SMN2L3MBTL1CYP2C9 | |
| SCHEMBL13873779 | 0.78 | EPHX2 (0.62) | SPREPHX2FAAHCYP2C9VNN1 | |
| SCHEMBL13873598 | 0.78 | SPR (0.45) | SPREPHX2FAAHL3MBTL1CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090111791-A1 | Soluble Epoxide Hydrolase Inhibitors and Methods of Using Same | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-04-30 | — | — | US | disclosed |
| US-20090111791-A1 | Soluble Epoxide Hydrolase Inhibitors and Methods of Using Same | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-04-30 | — | — | US | disclosed |
| WO-2007106705-A1 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS AND METHODS OF USING SAME | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-09-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090111791-A1 | Soluble Epoxide Hydrolase Inhibitors and Methods of Using Same | EPHX1, EPHX2, NCEH1 | SPR 61/4885P2RX7 1781/4885EPHX2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.